SAFETY AND EFFICACY OF PARAVALVULAR LEAK CLOSURE IN POST TAVR PATIENTS: A SINGLECENTER EXPERIENCE

Authors

• Omar S. Abdelhai, Henry Ford HealthFollow
• Mustafa Mohammed, Henry Ford HealthFollow
• Tiberio M. Frisoli, Henry Ford HealthFollow
• James C. Lee, Henry Ford HealthFollow
• William W. O’Neill, Henry Ford HealthFollow
• Bryan Zweig, Henry Ford HealthFollow
• Brian P. O’Neill, Henry Ford HealthFollow
• John Dawdy, Henry Ford HealthFollow
• Pedro Engel Gonzalez, Henry Ford HealthFollow
• Pedro A. Villablanca, Henry Ford HealthFollow

Recommended Citation

Abdelhai OS, Mohammed M, Frisoli TM, Lee JC, O’Neill WW, Zweig B, O’Neill BP, Dawdy J, Engel Gonzalez P, Villablanca PA. SAFETY AND EFFICACY OF PARAVALVULAR LEAK CLOSURE IN POST TAVR PATIENTS: A SINGLECENTER EXPERIENCE. J Am Coll Cardiol 2025; 85(12):924.

Document Type

Conference Proceeding

Publication Date

4-1-2025

Publication Title

J Am Coll Cardiol

Keywords

argipressin, adverse device effect, aged, clinical article, comorbidity, complication, conference abstract, female, heart failure, human, hyperlipidemia, long term survival, male, paravalvular leak, prevention, retrospective study, surgery, transcatheter aortic valve implantation, ventricular septal occluder

Abstract

Background: Paravalvular leak (PVL) is a notable complication following transcatheter aortic valve replacement (TAVR) and is associated with adverse impacts on both short- and long-term survival. This study aims to assess the safety and efficacy of PVL closure in a singlecenter experience. Methods We retrospectively analyzed all patients who underwent PVL closure post TAVR at Henry Ford Hospital between 2012 and 2022. Data collected included patient demographics, types and number of devices used, severity of residual PVL post-closure, and overall success rates. Severity of PVL was categorized as severe, moderate, and mild. Results Fifty patients (median age: 80 for females [n=32], 75 for males [n=18]) underwent attempted PVL closure. Comorbidities included hypertension, diabetes, hyperlipidemia, and heart failure. The AVP II plug Amplatzer was the most used device (72%, n=36), followed by Amplatzer Muscular VSD occluders (28%, n=14). On average, two devices were used per procedure. Post-intervention, all patients had minimal or no residual leak, with significant improvement in PVL severity (Figure 1). Conclusion This single-center experience demonstrates that percutaneous PVL closure after TAVR is a safe and effective procedure, as illustrated by the significant reduction in paravalvular leak severity (Figure 1). The use of Amplatzer devices, particularly the AVP II plug, resulted in a high technical success rate with minimal residual PVL. [Formula presented]

Volume

85

Issue

12

First Page

924